These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 27138005)

  • 21. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 23. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
    Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
    J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany.
    Schwarze-Zander C; Draenert R; Lehmann C; Stecher M; Boesecke C; Sammet S; Wasmuth JC; Seybold U; Gillor D; Wieland U; Kümmerle T; Strassburg CP; Mankertz A; Eis-Hübinger AM; Jäger G; Fätkenheuer G; Bogner JR; Rockstroh JK; Vehreschild JJ
    Epidemiol Infect; 2017 Jan; 145(2):236-244. PubMed ID: 27780480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low immunity against vaccine preventable diseases in Turkish HIV cohort.
    Candevir A; Kuşcu F; Yıldırım F; Kömür S; Şentürk GÇ; İnal AS; Eser F; Çetiner S; Kurtaran B; Taşova Y
    Turk J Med Sci; 2021 Oct; 51(5):2311-2317. PubMed ID: 33984893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.
    Waaijenborg S; Hahné SJ; Mollema L; Smits GP; Berbers GA; van der Klis FR; de Melker HE; Wallinga J
    J Infect Dis; 2013 Jul; 208(1):10-6. PubMed ID: 23661802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
    Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
    Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
    Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
    Mahamud A; Masunu-Faleafaga Y; Walls L; Williams N; Garcia P; Teshale E; Williams R; Dulski T; Bellini WJ; Kutty PK
    Vaccine; 2013 Aug; 31(36):3683-7. PubMed ID: 23770334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
    Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroepidemiology of measles, mumps and rubella virus infections in normal children and adults in southern Granada, Spain: response to a vaccination programme.
    Gutiérrez J; Rodríguez M; Huber E; Muñoz A; Piédrola G; Maroto C
    Microbios; 1996; 88(356):143-8. PubMed ID: 9141711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2010 May; 50(10):1415-8. PubMed ID: 20377409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
    Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
    An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.